SV2A and schizophrenia: Longitudinal combined PET-MRS studies are needed to test whether there is evidence for progressive loss of glutamatergic terminals in schizophrenia, a change in the SV2A-glutamate relationships over time, and possible effects of medication on these relationships, as seen in longitudinal PET-MRS studies of other neurobiological systems in schizophrenia [56].